title: In vitro characterizations of mesoporous hydroxyapatite as a controlled release delivery device for VEGF in orthopedic applications.
abstract: Following bone implant surgery, prolonged ischemic conditions at the implant site often result in postsurgical complications like failure of osseointegration at the bone-implant interface which can lead to implant failure. Thus, restoration of the vascular supply is paramount to the proper development of the bone. High surface area mesostructured materials have been shown to be attractive candidates for bone regeneration to enhance cell adhesion and cell proliferation. This study uses hydroxyapatite, a naturally occurring mineral in the bone, fabricated to a range of suitable pore sizes, infused with vascular endothelial growth factor (VEGF), to be progressively released to stimulate revascularization. In this study, several characterizations including nitrogen adsorption analysis, Fourier-transformed infrared spectroscopy, X-ray diffraction, field emission scanning electron microscope, and transmission electron microscope were used to evaluate the synthesized mesoporous hydroxyapatite (MHA). The results showed that MHA can gradually release VEGF for enhancing revascularization, which is beneficial for orthopedic applications.
authors: Department of Orthopaedic Surgery, National University of Singapore, Kent Ridge, Singapore 119074, Singapore.
authors: Chye Khoon
authors: CK
authors: Poh
authors: Suxiu
authors: S
authors: Ng
authors: Tee Yong
authors: TY
authors: Lim
authors: Hark Chuan
authors: HC
authors: Tan
authors: Joachim
authors: J
authors: Loo
authors: Wilson
authors: W
authors: Wang
mesh_terms: D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D003692:Delayed-Action Preparations / Q000737:chemistry*; D017886:Durapatite / Q000737:chemistry*; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D016062:Porosity; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D003692:Delayed-Action Preparations; D042461:Vascular Endothelial Growth Factor A; D017886:Durapatite